A Holistic View of GLP 1R Agonist–Mediated Cellular Response Revealed Through Orthogonal Technologies

Significance of the topic

Glucagon-like peptide-1 receptor (GLP1R) agonists are therapeutically important for type 2 diabetes and obesity and have growing influence across metabolic research. Profiling how GLP1R agonists reprogram cellular metabolism is critical for drug development, safety assessment, and mechanistic understanding of on- and off-target effects. Combining orthogonal techniques that report receptor activation, cellular bioenergetics, imaging phenotypes, and molecular metabolite/lipid changes provides a holistic view linking receptor engagement to downstream metabolic consequences.

Objectives and study overview

The study aimed to integrate complementary cellular analysis technologies to characterize GLP1R agonist–mediated responses in a HEK293 cell line engineered to express GLP1R. Specific goals included confirming receptor activation, assessing changes in cellular bioenergetics and morphology, and resolving molecular-level alterations in metabolites and lipids under varied nutrient/growth conditions and fatty acid supplementation. Two clinically relevant agonists (liraglutide and semaglutide) were compared across growth conditions including serum-replete, serum-free, and free fatty acid (FFA)-supplemented media.

Methodology and instrumentation

Key experimental elements and analytical workflows:

• Cell model and treatments: HEK293 cells stably expressing GLP1R were cultured and exposed for 24 h to growth media variants: 10% FBS (serum), serum-free (SF), SF with 0.1% FBS plus palmitate-BSA or defined palmitic/oleic acid ratios, and GLP1R agonists liraglutide or semaglutide at multiple concentrations.
• Receptor activation and imaging: cAMP accumulation (cAMP-Glo) and live-cell fluorescence imaging performed on an Agilent BioTek Cytation 9 to quantify agonist potency, intracellular cAMP changes, and BODIPY/phalloidin/Hoechst morphology and neutral lipid staining.
• Cellular bioenergetics: Seahorse XF Pro Analyzer (Mito Stress Test) measured oxygen consumption rate (OCR), ATP production rates, coupling efficiency, proton leak, and glycolytic contribution after 24 h pretreatment.
• Metabolomics and lipidomics: A dual extraction protocol (metabolite + lipid fractions) was applied. Metabolite extracts were analyzed by HILIC-Z LC with an Agilent 6495D LC/TQ in negative mode. Lipid extracts were analyzed by optimized reversed-phase LC with an Agilent Revident LC/Q-TOF in positive mode. Data processing used MassHunter Explorer/Quant, LipidMatch Suite, and Mass Profiler Professional (MPP).

Results and discussion

Principal findings and their interpretation:

• Receptor activation and imaging: GLP1R-HEK293 cells responded to liraglutide and semaglutide with EC50 values in the low nanomolar range (reported ~3 nM for liraglutide and ~4 nM for semaglutide), consistent with expected potency. cAMP elevation measured by both the luminescence assay and targeted metabolomics supported effective receptor signaling. BODIPY imaging showed FFA-dependent lipid droplet accumulation, but GLP1R agonist treatment did not appreciably change droplet formation; morphological alterations were noted with agonist treatment.
• Bioenergetic reprogramming (Seahorse XF): Liraglutide pretreatment for 24 h induced a shift toward a more glycolytic phenotype across media conditions. In serum-starved cells, liraglutide decreased mitochondrial coupling efficiency and increased proton leak, producing a significant reduction in mitochondrial ATP production. Overall results indicate increased reliance on glycolysis and reduced mitochondrial efficiency under certain stress conditions.
• Metabolomics (LC/QQQ): Targeted analysis detected 222 metabolites. Consistent with assays, cAMP increased while ATP decreased after agonist treatment. Differential analysis identified 71 metabolites altered across conditions and drug treatments. Observed patterns included decreased nucleotide triphosphates with concomitant increases in monophosphates and nucleosides—interpreted as nucleotide degradation associated with AMPK activation and low-energy stress. Additional signatures suggested increased amino acid catabolism to feed the TCA cycle, decreased TCA intermediates in some contexts, and activation of the pentose phosphate pathway (PPP) consistent with elevated NADPH demand and oxidative stress responses.
• Lipidomics (LC/Q-TOF): FFA supplementation produced predictable increases in triacylglycerol content and altered esterified fatty acyl composition in line with supplied palmitate/oleate ratios, matching imaging evidence for lipid droplet formation. GLP1R agonist exposure did not produce significant changes in the bulk lipidome, corroborating imaging results that drug treatment did not affect lipid droplet accumulation.
• Concordance across platforms: The multi-technology approach provided cross-validated insights—cAMP increases seen by assay and metabolomics; decreased ATP and altered ATP production consistent between Seahorse and metabolite profiling; lipidome and imaging agreed on FFA-driven lipid accumulation and lack of agonist effect.

Benefits and practical applications of the method

Integrating imaging, receptor assays, bioenergetics, and LC/MS-based metabolomics/lipidomics yields a robust pipeline for translational profiling of drug candidates. Practical advantages include:

• Ability to link receptor occupancy and primary signaling (cAMP) to downstream metabolic and energetic phenotypes.
• Higher confidence in mechanistic interpretation by cross-validating phenotypes across orthogonal readouts.
• Relevance to safety and efficacy assessment: detection of metabolic reprogramming, mitochondrial dysfunction, or stress signatures that could inform compound optimization and risk assessment.
• Flexibility to evaluate nutrient context and potential interaction with lipid environments (FFA supplementation) to reveal condition-dependent effects.

Future trends and potential applications

Potential extensions and emerging directions building on this approach:

• Higher-content or higher-throughput implementations combining automated sample prep, multiplexed assays, and targeted dMRM workflows to increase screening capacity for lead optimization.
• Single-cell or spatial metabolomics to resolve cell-to-cell heterogeneity in metabolic responses to GLP1R agonists and microenvironmental influences.
• Integration with transcriptomics and proteomics to build multi-omics causal networks linking receptor signaling to metabolic regulation.
• Application to more physiologically relevant models (primary cells, iPSC-derived tissues, co-culture or organoid systems) to improve translational validity.
• Use of advanced MS instrumentation and computational lipid annotation pipelines to expand lipidome coverage and structural resolution of altered species.

Conclusion

This study demonstrates that clinically relevant GLP1R agonists (liraglutide and semaglutide) provoke measurable metabolic reprogramming in GLP1R-expressing HEK293 cells without altering FFA-driven lipid droplet formation. Key outcomes include increased intracellular cAMP, reduced cellular ATP, a shift toward glycolytic ATP production, and decreased mitochondrial coupling efficiency under serum-starved stress. Orthogonal measurement platforms provided consistent, complementary evidence and highlight the value of integrated cellular phenotyping for drug mechanism and safety assessment.

References

1. Van de Bittner G, et al. An Automated Dual Metabolite + Lipid Sample Preparation Workflow for Mammalian Cell Samples. Agilent Technical Overview 5994-5065EN, 2022.
2. Yannell K, et al. An End-to-End Targeted Metabolomics Workflow. Agilent Application Note 5994-5628EN, 2023.
3. Hyunh K, et al. LC/MS dMRM Method Refinement Expands Targeted Lipidomics Studies from Plasma to Cells and Tissues. Agilent Application Note 5994-8365EN, 2026.
4. Sartain M, et al. Lipid Insight Unblocked: Combining Nontargeted LC/MS Chemometrics With Automated Lipid Annotation. ASMS 2026 Poster WP 504.